<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3273">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031601</url>
  </required_header>
  <id_info>
    <org_study_id>QLHX-0531</org_study_id>
    <nct_id>NCT02031601</nct_id>
  </id_info>
  <brief_title>Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer</brief_title>
  <acronym>TCL-1</acronym>
  <official_title>Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare the efficacy and safety of chemotherapy plus intercalated
      EGFR-tyrosine kinase inhibitors (TKI) combination therapy with TKI alone therapy as
      first-line treatment for patients with non-small-cell lung cancer (NSCLC).

      Methods: Patients with untreated, stage IIIB/IV, EGFR mutation-positive NSCLC will be
      randomly assigned to combination therapy group (receiving four cycles of docetaxel or
      pemetrexed (on day 1) plus platinum  (on day 1) with intercalated TKI (gefitinib, erlotinib
      or Icotinib, on day 2-15) every 3 weeks) or TKI alone therapy (gefitinib, erlotinib or
      Icotinib, daily). All patients were continued to receive TKI until progression or
      unacceptable to toxicity or death. The primary endpoint was progression-free survivial
      (PFS).

      Expected results: PFS of combination therapy group will be prolonged to nineteen months
      while PFS of TKI alone therapy group is ten months. Overall survival (OS) of combination
      therapy group will be prolonged to 36 months while OS of TKI alone therapy group is 26
      months.

      Hypothesis: Platinum-based chemotherapy plus intercalated TKI combination therapy as
      first-line treatment will prolong PFS and OS for patients with NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) is defined to be the time from randomization to progression of disease or death, whichever occurs first. Progressive disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs), Serious Adverse Events (SAEs), laboratory data</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions:
Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI alone therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Interventions:
Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Conmana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum (cisplatin or carboplatin)</intervention_name>
    <description>cisplatin -- 75mg/m2  ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg po once a day daily until disease progression</description>
    <arm_group_label>TKI alone therapy</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>250mg po once a day daily until disease progression</description>
    <arm_group_label>TKI alone therapy</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>125mg po three times a day daily until disease progression</description>
    <arm_group_label>TKI alone therapy</arm_group_label>
    <other_name>Conmana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;=18 years of age;

          -  Advanced (stage IIIB/IV) non-small-cell lung cancer;

          -  Although stageⅠ-ⅢA, have contraindications to surgery;

          -  EGFR mutation-positive (EGFR exon-18, exon-19 or exon-21);

          -  Measurable disease;

          -  ECOG Performance Status 0 or 1 or 2.

        Exclusion Criteria:

          -  Wild-type EGFR;

          -  Prior exposure to agents directed at the HER axis;

          -  Prior chemotherapy or systemic anti-tumor therapy after advanced disease;

          -  Unstable systemic disease;

          -  Any other malignancy within last 5 years, except cured basal cell cancer of skin or
             cured cancer in situ of cervix;

          -  Brain metastasis or spinal cord compression.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Li, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Vice Director</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital</investigator_affiliation>
    <investigator_full_name>Qian Qi</investigator_full_name>
    <investigator_title>assistant director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
